Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccines: progress and challenges.

John J Donnelly1, Britta Wahren, Margaret A Liu

  • 1Chiron Vaccines, Chiron Corporation, Emeryville, CA 94608, USA. john_donnelly@chiron.com

Journal of Immunology (Baltimore, Md. : 1950)
|July 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV-1 Protease as DNA Immunogen against Drug Resistance in HIV-1 Infection: DNA Immunization with Drug Resistant HIV-1 Protease Protects Mice from Challenge with Protease-Expressing Cells.

Cancers·2023
Same author

DNA and mRNA Vaccines for Chronic Viral Infections and Cancer: Rationale, Mechanisms, and Progress.

Cancers·2022
Same author

Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev.

Molecular biology reports·2022
Same author

60 Years of viral vaccines.

Human vaccines & immunotherapeutics·2022
Same author

WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021.

Emerging microbes & infections·2022
Same author

Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.

Microorganisms·2021
Same journal

Optineurin restrains IL-17-associated neuroinflammation in trigeminal ganglia to preserve sensory function after ocular HSV-1 infection.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Crystal structure and immune single-cell atlas provide insights into the functional divergence of type I IFNs in fish.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Increased Nur77 is disconnected from TCR affinity in insulin-specific Tregs.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

FTR85 negatively regulates type I IFN antiviral signaling pathway by promoting K48-linked polyubiquitination of IRF3.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

An MR1-specific nanobody capable of blocking MR1T cell activation.

Journal of immunology (Baltimore, Md. : 1950)·2026
See all related articles

DNA vaccines show promise for infectious diseases, cancer, and autoimmune conditions, but their potency in humans remains a challenge. Further research into immunological mechanisms is needed to improve efficacy.

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Plasmid DNA demonstrated the ability to generate protective immune responses in vivo.
  • DNA vaccines have advanced into human clinical trials for infectious diseases, cancer, autoimmune diseases, and allergies.
  • DNA vaccines are utilized as laboratory tools in proteomics and antigen presentation studies.

Purpose of the Study:

  • To provide a background on DNA vaccine development.
  • To review insights into the immunological mechanisms of DNA vaccines.
  • To address the challenges in translating preclinical efficacy to clinical reality.

Main Methods:

  • This is a review article, synthesizing existing research and data.
  • It examines the immunological mechanisms underlying DNA vaccine responses.

Related Experiment Videos

  • It discusses the translation of preclinical findings to human clinical trials.

    • Main Results:

    • Despite widespread development, DNA vaccines exhibit disappointing potency in human trials.
    • Efficacy in preclinical models has not consistently translated into clinical success.
    • Varied immunological mechanisms contribute to DNA vaccine-induced immune responses.

    Conclusions:

    • Significant challenges persist in optimizing DNA vaccine potency for human application.
    • Understanding the complex immunological mechanisms is crucial for improving DNA vaccine efficacy.
    • Further research is required to bridge the gap between preclinical promise and clinical reality for DNA vaccines.